Altimmune abandons ship on intranasal Covid-19 vaccine, refocusing on liver, obesity programs after trial flop

Kyle Blankenship

Among the also-rans in the Covid-19 vaccine race, small biotech Altimmune hoped to ride a novel intranasal formulation for its own candidate to market but …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Altimmune abandons ship on intranasal Covid-19 vaccine, refocusing on liver, obesity programs after trial flop

Kyle Blankenship

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

FDA meeting to pick next winter's flu shot is canceled, in ominous sign for US vaccine policy

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

After rejection, Regeneron seeks accelerated approval of bispecific for only one of two types of lymphoma

Where the money is: The top 100 venture investors in biotech

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

How AI can address ongoing challenges in the life sciences industry

Al­tim­mune aban­dons ship on in­tranasal Covid-19 vac­cine, re­fo­cus­ing on liv­er, obe­si­ty pro­grams af­ter tri­al flop

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Altimmune abandons ship on intranasal Covid-19 vaccine, refocusing on liver, obesity programs after trial flop